Search

Your search keyword '"Pansini F."' showing total 353 results
Start Over Author "Pansini F."
353 results on '"Pansini F."'

4. Acute and intermediate toxicity of 3-week radiotherapy with simultaneous integrated boost using TomoDirect: prospective series of 287 early breast cancer patients

Author

Dicuonzo, S, Leonardi, M, Raimondi, S, Corrao, G, Bagnardi, V, Gerardi, M, Morra, A, Zerella, M, Zaffaroni, M, Pansini, F, Cattani, F, Luraschi, R, Fodor, C, Veronesi, P, Orecchia, R, Rojas, D, Jereczek-Fossa, B, Dicuonzo S., Leonardi M. C., Raimondi S., Corrao G., Bagnardi V., Gerardi M. A., Morra A., Zerella M. A., Zaffaroni M., Pansini F., Cattani F., Luraschi R., Fodor C., Veronesi P., Orecchia R., Rojas D. P., Jereczek-Fossa B. A., Dicuonzo, S, Leonardi, M, Raimondi, S, Corrao, G, Bagnardi, V, Gerardi, M, Morra, A, Zerella, M, Zaffaroni, M, Pansini, F, Cattani, F, Luraschi, R, Fodor, C, Veronesi, P, Orecchia, R, Rojas, D, Jereczek-Fossa, B, Dicuonzo S., Leonardi M. C., Raimondi S., Corrao G., Bagnardi V., Gerardi M. A., Morra A., Zerella M. A., Zaffaroni M., Pansini F., Cattani F., Luraschi R., Fodor C., Veronesi P., Orecchia R., Rojas D. P., and Jereczek-Fossa B. A.

Abstract

Aims: To report toxicity of a hypofractionated scheme of whole-breast (WB) intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) to the tumor bed (TB) using Tomotherapy® with Direct modality. Methods: Patients with early breast cancer, undergoing radiotherapy (RT) in 15 daily fractions to WB (prescription dose 40.05 Gy) and SIB to the TB (48 Gy), between 2013 and 2017, was analyzed. Primary endpoint was acute and intermediate toxicity assessed at the end and within 6 months from RT, according to Radiation Therapy Oncology Group (RTOG) scale. Secondary endpoints included early chronic toxicity at 12-months follow-up, using the Late Effects Normal Tissue Task Subjective, Objective, Management, and Analytic (LENT-SOMA) scale, and cosmesis using Harvard criteria. Results: The study population was of 287 patients. Acute and intermediate toxicity was collected among 183 patients with data available at the end of RT and within 6 months, 85 (46%) experienced G2 toxicity and 84 (46%) G1 toxicity, while 14 (8%) did not report toxicity at any time. A significant reduction of any grade toxicity was observed between the two time points, with the majority of patients reporting no clinically relevant toxicity at 6 months. At univariate analysis, age < 40 years, breast volume > 1000 cm3 and Dmax ≤ 115% of prescription dose were predictive factors of clinically relevant acute toxicity (G ≥ 2) at any time. At multivariable analysis, only age and breast volume were confirmed as predictive factors, with Relative Risks (95% Confidence Intervals): 2.02 (1.13–3.63) and 1.84 (1.26–2.67), respectively. At 12-month follow-up, 113 patients had complete information on any toxicity with 53% of toxicity G < 2, while cosmetic evaluation, available for 102 patients, reported a good–excellent result for 86% of patients. Conclusions: Hypofractionated WB IMRT with a SIB to the TB, delivered with TomoDirect modality, is safe and well-tolerated. Most patients reporte

Published
2021

5. Finding safe dose-volume constraints for re-irradiation with SBRT of patients with prostate cancer relapse: The IEO experience

Author

Augugliaro, M, Marvaso, G, Cambria, R, Pepa, M, Bagnardi, V, Frassoni, S, Pansini, F, Patricia Rojas, D, Colombo, F, Iuliana Fodor, C, Musi, G, Petralia, G, De Cobelli, O, Cattani, F, Orecchia, R, Zerini, D, Alicja Jereczek-Fossa, B, Augugliaro M., Marvaso G., Cambria R., Pepa M., Bagnardi V., Frassoni S., Pansini F., Patricia Rojas D., Colombo F., Iuliana Fodor C., Musi G., Petralia G., De Cobelli O., Cattani F., Orecchia R., Zerini D., Alicja Jereczek-Fossa B., Augugliaro, M, Marvaso, G, Cambria, R, Pepa, M, Bagnardi, V, Frassoni, S, Pansini, F, Patricia Rojas, D, Colombo, F, Iuliana Fodor, C, Musi, G, Petralia, G, De Cobelli, O, Cattani, F, Orecchia, R, Zerini, D, Alicja Jereczek-Fossa, B, Augugliaro M., Marvaso G., Cambria R., Pepa M., Bagnardi V., Frassoni S., Pansini F., Patricia Rojas D., Colombo F., Iuliana Fodor C., Musi G., Petralia G., De Cobelli O., Cattani F., Orecchia R., Zerini D., and Alicja Jereczek-Fossa B.

Abstract

Aim: The primary aim of this study is to provide preliminary indications for safe constraints of rectum and bladder in patients re-irradiated with stereotactic body RT (SBRT). Methods: Data from patients treated for prostate cancer (PCa) and intraprostatic relapse, from 1998 to 2016, were retrospectively collected. First RT course was delivered with 3D conformal RT techniques, SBRT or volumetric modulated arc therapy (VMAT). All patients underwent re-irradiation with SBRT with heavy hypofractionated schedules. Cumulative dose-volume values to organs at risk (OARs) were computed and possible correlation with developed toxicities was investigated. Results: Twenty-six patients were included. Median age at re-irradiation was 75 years, mean interval between the two RT courses was 5.6 years and the median follow-up was 47.7 months (13.4–114.3 months). After re-irradiation, acute and late G ≥ 2 GU toxicity events were reported in 3 (12%) and 10 (38%) patients, respectively, while late G ≥ 2 GI events were reported in 4 (15%) patients. No acute G ≥ 2 GI side effects were registered. Patients receiving an equivalent uniform dose of the two RT treatments < 131 Gy appeared to be at higher risk of progression (4-yr b-PFS: 19% vs 33%, p = 0.145). Cumulative re-irradiation constraints that appear to be safe are D30% < 57.9 Gy for bladder and D30% < 66.0 Gy, D60% < 38.0 Gy and V122.1 Gy < 5% for rectum. Conclusion: Preliminary re-irradiation constraints for bladder and rectum have been reported. Our preliminary investigation may serve to clear some grey areas of PCa re-irradiation.

Published
2021

6. PO-1546 Dosimetric characterization of PLA 3D printed boluses for external beam radiotherapy

Author

Pepa, M., primary, Gugliandolo, S.G., additional, Pansini, F., additional, Vavassori, A., additional, Vincini, M.G., additional, Zaffaroni, M., additional, Alterio, D., additional, Rajendran, S., additional, Pillai, S.P., additional, Volpe, S., additional, Marvaso, G., additional, Corrao, G., additional, Cattani, F., additional, Colosimo, B.M., additional, and Jereczek-Fossa, B.A., additional

Published
2022
Full Text
View/download PDF

8. Optimal basis sets for CBS extrapolation of the correlation energy: oVxZ and oV(x+d)Z.

Author

Varandas, A. J. C. and Pansini, F. N. N.

Subjects
*EXTRAPOLATION, *IONIZATION energy, *ATOMIZATION, *CASE studies, *MOLECULAR polarizability
Abstract

We seek correlation consistent double- and triple-zeta basis sets that perform optimally for extrapolating the correlation energy to the one-electron complete basis set limit. Since the methods used are approximate, the novel basis sets become method specific in the sense of performing best for the chosen level of theory. Such basis sets are also shown to perform accurately for tensorial properties and do not significantly alter the Hartree-Fock energy. Quantitatively, the extrapolated correlation energies from (oVdZ, oVtZ) outperform typically by three- to fivefold those obtained from traditional ansatzes with similar flexibility, thus being (VtZ, VqZ) type or even better. They may even outperform explicitly correlated ones. Not surprisingly, the outperformance in relative energies (e.g., atomization and dissociation energies, and ionization potential) is somewhat downscaled, albeit consistently better than with traditional basis sets. As a case study, we also consider the polarizability of p-nitroaniline, a sizeable system for which complete basis set (CBS)(oVdZ, oVtZ) calculations are shown to outperform equally expensive CBS(VdZ, VtZ) results. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

12. Salvage stereotactic external beam re-irradiation for prostate cancer local failure: finding safe dose constraints for principal organs at risk

Author

Cambria, R., primary, Zerini, D., additional, Pansini, F., additional, Rojas, D.P., additional, Pepa, M., additional, Colombo, F., additional, Marvaso, G., additional, Fodor, C.I., additional, Bagnardi, V., additional, Frassoni, S., additional, Cattani, F., additional, and Jereczek-Fossa, B.A., additional

Published
2021
Full Text
View/download PDF

15. Reactions induced by 35 MeV 6He beam on 12C and 14C

Author

Milin, M., Maggio, A., Acosta, L., Alvarez, M. A.G., Angulo, C., Casarejos, E., de Séréville, N., Di Pietro, A., Figuera, P., Fisichella, M., Freer, M., Keutgen, Th., Lattuada, M., Majer, M., Martel, I., Miljanić, D., Pansini, F., Price, D., Sánchez-Benitez, A. M., Soić, N., Uroić, M., and Zadro, M.

Published
2007
Full Text
View/download PDF

17. PO-0937: Partial breast re-irradiation with IMRT for local recurrence after whole breast radiotherapy

Author

Arculeo, S., primary, Frassoni, S., additional, Cavallo, I., additional, Dicuonzo, S., additional, Gerardi, M.A., additional, Morra, A., additional, Dell'Acqua, V., additional, Cattani, F., additional, Comi, S., additional, Veronesi, P., additional, Pansini, F., additional, Galimberti, V., additional, Fodor, C., additional, Bagnardi, V., additional, Orecchia, R., additional, Leonardi, M.C., additional, and Jereczek-Fossa, B.A., additional

Published
2020
Full Text
View/download PDF

20. Narrowing the error in electron correlation calculations by basis set re-hierarchization and use of the unified singlet and triplet electron-pair extrapolation scheme: Application to a test set of 106 systems.

Author

Varandas, A. J. C. and Pansini, F. N. N.

Subjects
*ERROR analysis in mathematics, *ELECTRON correlation calculations, *BASIS sets (Quantum mechanics), *EXTRAPOLATION, *ATOMIZATION, *CLUSTER analysis (Statistics)
Abstract

A method previously suggested to calculate the correlation energy at the complete one-electron basis set limit by reassignment of the basis hierarchical numbers and use of the unified singlet- and triplet-pair extrapolation scheme is applied to a test set of 106 systems, some with up to 48 electrons. The approach is utilized to obtain extrapolated correlation energies from raw values calculated with second-order M0ller-Plesset perturbation theory and the coupled-cluster singles and doubles excitations method, some of the latter also with the perturbative triples corrections. The calculated correlation energies have also been used to predict atomization energies within an additive scheme. Good agreement is obtained with the best available estimates even when the (d, t) pair of hierarchical numbers is utilized to perform the extrapolations. This conceivably justifies that there is no strong reason to exclude double-zeta energies in extrapolations, especially if the basis is calibrated to comply with the theoretical model. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

22. PO-0819 Stereotactic Radiation Therapy in Oligometastatic Colorectal Cancer: 102 patients and 150 lesions

Author

ZERELLA, M.A., primary, Dell'Acqua, V., additional, Surgo, A., additional, Pupuleku, F. Kraja, additional, Kobiela, J., additional, Spychalski, P., additional, Francia, C.M., additional, Ciardo, D., additional, Fodor, C., additional, Pansini, F., additional, Vigorito, S., additional, Cattani, F., additional, Leonardi, M.C., additional, and Fossa, B.A. Jereczek, additional

Published
2019
Full Text
View/download PDF

25. EP-1310 Toxicity evaluation of a hypofractionated WBRT with SIB for breast cancer using TomoDirect

Author

Dicuonzo, S., primary, Leonardi, M.C., additional, Raimondi, S., additional, Miglietta, E., additional, Gerardi, M.A., additional, Morra, A., additional, Dell'Acqua, V., additional, Surgo, A., additional, Rojas, D.P., additional, Pansini, F., additional, Luraschi, R., additional, Cattani, F., additional, Fodor, C., additional, Veronesi, P., additional, Orecchia, R., additional, and Jereczek-Fossa, B.A., additional

Published
2019
Full Text
View/download PDF

27. Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday

Author

Lazzari, R, Ronchi, S, Gandini, S, Surgo, A, Volpe, S, Piperno, G, Comi, S, Pansini, F, Fodor, C, Orecchia, R, Tomao, F, Parma, G, Colombo, N, Jereczek-Fossa, B, Lazzari, Roberta, Ronchi, Sara, Gandini, Sara, Surgo, Alessia, Volpe, Stefania, Piperno, Gaia, Comi, Stefania, Pansini, Floriana, Fodor, Cristiana, Orecchia, Roberto, Tomao, Federica, Parma, Gabriella, Colombo, Nicoletta, Jereczek-Fossa, Barbara Alicja, Lazzari, R, Ronchi, S, Gandini, S, Surgo, A, Volpe, S, Piperno, G, Comi, S, Pansini, F, Fodor, C, Orecchia, R, Tomao, F, Parma, G, Colombo, N, Jereczek-Fossa, B, Lazzari, Roberta, Ronchi, Sara, Gandini, Sara, Surgo, Alessia, Volpe, Stefania, Piperno, Gaia, Comi, Stefania, Pansini, Floriana, Fodor, Cristiana, Orecchia, Roberto, Tomao, Federica, Parma, Gabriella, Colombo, Nicoletta, and Jereczek-Fossa, Barbara Alicja

Abstract

Purpose: To evaluate stereotactic body radiation therapy (SBRT) for metachronous oligometastatic ovarian cancer patients in terms of local control, delay of systemic treatment, survival outcomes, and toxicity. Methods and Materials: Retrospective data collection from a single institution was performed. The inclusion criteria were as follows: (1) oligorecurrent or oligoprogressive disease in ovarian cancer patients during or after systemic therapy; (2) surgery or other local therapies not feasible; and (3) relative contraindication to systemic therapy for reasons such as unavailability of additional chemotherapy lines or refusal of the patient. Tumor response and toxicity were evaluated using the Response Evaluation Criteria in Solid Tumors and the Common Terminology Criteria for Adverse Events version 4.03, respectively. A new systemic therapy regimen was started after an SBRT treatment course in 57 of 109 cases (52.3%). Local progression–free survival, progression-free survival, and overall survival were calculated via the Kaplan-Meier method. The systemic treatment–free interval was calculated in cases without concomitant systemic therapy. Results: Between May 2012 and December 2016, 82 patients (156 lesions) underwent SBRT with a median dose of 24 Gy in 3 fractions. The median follow-up period was 17.4 months. Patients received a median of 3 systemic therapy regimens prior to SBRT. Concomitant systemic therapy was performed for 29 lesions (18.6%). Among 152 evaluable lesions, a complete radiologic response, partial response, stabilization, and progressive disease were observed in 91 (60%), 26 (17%), 24 (16%), and 11 (7%), respectively. No grade 3 or 4 acute or late toxicities were observed. The median systemic treatment–free interval after SBRT was 7.4 months, and 1 of 3 patients was disease free at 1 year after SBRT. The actuarial 2-year local progression–free survival, progression-free survival, and overall survival rates were 68%, 18%, and 71%, respectively. T

Published
2018

34. EP-1339: Feasibility and efficacy of moderately hypofractionated radiotherapy in high risk prostate cancer

Author

Marvaso, G., primary, Riva, G., additional, Bassi, C., additional, Fodor, C., additional, Ciardo, D., additional, Zerini, D., additional, Timon, G., additional, Surgo, A., additional, Maucieri, A., additional, Pansini, F., additional, De Marco, P., additional, Cattani, F., additional, De Cobelli, O., additional, Orecchia, R., additional, and Jereczek-Fossa, B., additional

Published
2017
Full Text
View/download PDF

35. PO-0660: Partial breast re-irradiation with IMRT in patients with local failure after conservative treatment

Author

Dicuonzo, S., primary, Spoto, R., additional, Leonardi, M.C., additional, Surgo, A., additional, Viola, A., additional, Augugliaro, M., additional, Pansini, F., additional, Cattani, F., additional, Galimberti, V., additional, Morra, A., additional, Dell’Acqua, V., additional, Orecchia, R., additional, and Jereczek-Fossa, B.A., additional

Published
2017
Full Text
View/download PDF

36. EP-1338: High precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion

Author

Riva, G., primary, Timon, G., additional, Ciardo, D., additional, Bazani, A., additional, Maestri, D., additional, De Lorenzo, D., additional, Pansini, F., additional, Cambria, R., additional, Cattani, F., additional, Marvaso, G., additional, Zerini, D., additional, Rojas, D.P., additional, Volpe, S., additional, Golino, F., additional, Scroffi, V., additional, Fodor, C., additional, Petralia, G., additional, De Cobelli, O., additional, Orecchia, R., additional, and Jereczek-Fossa, B.A., additional

Published
2017
Full Text
View/download PDF

37. Re-hierarquização e Extrapolações para o Limite do Conjunto de Base Completo

Author

PANSINI, F. N. N., GALVAO, B. R. L., MOTA, V. C., GONCALVES, S. V. B., LIMA, D. C. A., and CANAL NETO, A.

Subjects
Química Quântica-Metodologia, Hartree Fock, Átomos, Moléculas
Abstract

Made available in DSpace on 2018-08-01T22:30:01Z (GMT). No. of bitstreams: 1 tese_8896_Tese final Fernando Néspoli.pdf: 1384436 bytes, checksum: f3462b5c8d9880e7dec5565dd15bafb3 (MD5) Previous issue date: 2015-05-06 Um método sugerido previamente para calcular a energia de correlação no limite do conjunto de base completo pela redesignação dos números hierárquicos, e o uso do esquema de extrapolação unified singlet- and triplet-pair é aplicado a um conjunto de prova de 106 sistemas. A aproximação é utilizada para obter os valores extrapolados para energia de correlação, energia de atomização, anisotropia e polarizabilidade média no limite do conjunto de base completo, através de teoria de perturbação de segunda ordem de Møller-Plesset, método de coupled-cluster com excitações simples e duplas e coupled-cluster com excitações simples e duplas com correções triplas perturbativas. Uma boa concordância com as melhores estimativas disponíveis é obtida, mesmo quando o par de números hierárquicos (d, t) é usado para realizar a extrapolação. Com isso, é concebível justificar que não há razão física forte para excluir as energias dulpa-zeta em extrapolações, especialmente se a base é calibrada para obedecer ao modelo teórico. Além disso, um esquema simples de extrapolação unificado de um parâmetro é sugerido para extrapolar a energia de correlação de valência para o conjunto de base completo em espécies formadas por átomos de H até Ne. A performance do novo modelo é avaliada para a energia de correlação com um conjunto de de dados de 106 sistemas e, para polarizabilidade média, em um conjunto de 8 moléculas. Para as energias de correlação, os resultados são excelentes, na maioria das vezes melhores do que quando extrapolado com os mais populares protocolos de dois parâmetros disponíveis na literatura. Para a polarizabilidade, os resultados mostram uma melhora em relação aos valores ab initio, e uma boa concordância com os dados experimentais.

Published
2015

39. Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions.

Author

Dell'Acqua, V., Surgo, A., Kraja, F., Kobiela, J., Zerella, Maria Alessia, Spychalski, P., Gandini, S., Francia, C. M., Ciardo, D., Fodor, C., Ferrari, A. M., Piperno, G., Cattani, F., Vigorito, S., Pansini, F., Petz, W., Orecchia, R., Leonardi, M. C., and Jereczek-Fossa, B. A.

Abstract

To evaluate the local control (LC), progression free survival (PFS), out-field PFS, overall survival (OS), toxicity and failure predictors of SRT in a series of various sites oligometastatic CRC patients. Patients with oligometastatic CRC disease were analyzed retrospectively. The SRT prescribed dose was dependent on the lesion volume and its location. 102 consecutive oligometastatic CRC patients (150 lesions) were included. They underwent SRT between 2012 and 2015. Median prescription dose was 45 Gy (median dose/fraction was 15 Gy/3 fractions biological equivalent dose (BED10) 112.5 Gy). Median follow-up was 11.4 months. No patients experienced G3 and G4 toxicity. No progression was found in 82% (radiological response at 3 months) and 85% (best radiological response) out of 150 evaluable lesions. At 1 and 2 years: LC was 70% and 55%; OS was 90% and 90%; PFS was 37% and 27%; out-field PFS was 37% and 23% respectively. Progressive disease was correlated with BED10 (better LC when BED10 was ≥ 75 Gy (p < 0.0001)). In multivariate analysis, LC was higher in lesions with a Plpnning target volume (PTV) volume < 42 cm3 and BED10 ≥ 75 Gy. Patients with Karnofsky performance status < 90 showed higher out-field progression. SRT is an effective treatment for patients with oligometastases from CRC. Its low treatment-associated morbidity and acceptable LC make of SRT an option not only in selected cases. Further studies should be focused to clarify which patient subgroup will benefit most from this treatment modality and to define the optimal dose to improve LC while maintaining low toxicity profile. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

40. VERO® radiotherapy for low burden cancer: 789 patients with 957 lesions

Author

Orecchia, R, primary, Surgo, A, additional, Muto, M, additional, Ferrari, A, additional, Piperno, G, additional, Girardi, MA, additional, Comi, S, additional, Garibaldi, C, additional, Ciardo, D, additional, Bazani, A, additional, Golino, F, additional, Pansini, F, additional, Fodor, C, additional, Romanelli, P, additional, Maestri, D, additional, Scroffi, V, additional, Mazza, S, additional, and Jereczek-Fossa, BA, additional

Published
2016
Full Text
View/download PDF

42. OC-0448: Give me five: extreme hypofractionated IG-IMRT for organ confined prostate cancer

Author

Jereczek-Fossa, B.A., primary, Ciardo, D., additional, Colangione, S.P., additional, Fodor, C., additional, Zerini, D., additional, Cecconi, A., additional, Surgo, A., additional, Gerardi, M.A., additional, Muto, M., additional, Timon, G., additional, Comi, S., additional, Pansini, F., additional, Bazani, A., additional, Maestri, D., additional, Garioni, M., additional, Scroffi, V., additional, Cattani, F., additional, Cambria, R., additional, De Cobelli, O., additional, and Orecchia, R., additional

Published
2016
Full Text
View/download PDF

43. EP-1370: Stereotactic body radiotherapy in 117 oligometastatic lymph node recurrent prostate cancer patients

Author

Fanetti, G., primary, Jereczek-Fossa, B.A., additional, Fodor, C., additional, Francia, C.M., additional, Zerini, D., additional, Surgo, A., additional, Muto, M., additional, Gerardi, M.A., additional, Dicuonzo, S., additional, Cambria, R., additional, Garibaldi, C., additional, Pansini, F., additional, Bazani, A., additional, De Cobelli, O., additional, and Orecchia, R., additional

Published
2016
Full Text
View/download PDF

44. EP-1753: Intrafraction setup variability for breast Helical Tomotherapy

Author

Ricotti, R., primary, Ciardo, D., additional, Fattori, G., additional, Leonardi, M.C., additional, Morra, A., additional, Pansini, F., additional, Cambria, R., additional, Cattani, F., additional, Gianoli, C., additional, Riboldi, M., additional, Baroni, G., additional, Jereczek-Fossa, B.A., additional, and Orecchia, R., additional

Published
2016
Full Text
View/download PDF

47. Dosimetric impact of contouring variability for prostate cancer patients undergoing combined carbon ions/photons treatment (AIRC-IG 14300)

Author

Giandini, T., primary, Ciardo, D., additional, Carrara, M., additional, Russo, S., additional, Pansini, F., additional, Bazani, A., additional, Bedini, N., additional, Colangione, S.P., additional, Morlino, S., additional, Vischioni, B., additional, Bosetti, D., additional, Zerini, D., additional, Avuzzi, B., additional, Hasegawa, A., additional, Cattani, F., additional, Pignoli, E., additional, Valvo, F., additional, Jereczek-Fossa, B.A., additional, Valdagni, R., additional, and Orecchia, R., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results